Nektar Therapeutics
Nektar Therapeutics is an American clinical-stage biopharmaceutical company focused on discovering and developing novel targeted immunotherapies for autoimmune diseases and chronic inflammatory conditions. Its lead product candidate is rezpegaldesleukin, an interleukin-2 receptor pathway agonist designed to stimulate regulatory T-cells, which is advancing through Phase 3 clinical trials for moderate-to-severe atopic dermatitis and alopecia areata alongside studies in Type 1 diabetes. The company is also advancing NKTR-0165, a selective TNFR2 agonist antibody targeting autoimmune disorders such as multiple sclerosis and ulcerative colitis, as well as preclinical bispecific antibody programs. Without internally commercialized drugs, revenue consists primarily of non-cash royalty streams tied to legacy partnered assets, while research and clinical operations are funded through public equity offerings and balance sheet cash reserves. Headquartered in San Francisco, California, Nektar Therapeutics trades on the Nasdaq Stock Market under the ticker symbol NKTR. The company operates with a focused organization of roughly 100 to 150 employees dedicated to immunology research and clinical execution.
2 of the funds FundTelligence covers report a position in Nektar Therapeutics.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Nektar Therapeutics
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)